With the first successful implantation at the Saudi German Hospital in Dubai, Nyxoah has formally launched its Genio treatment in the Middle East, marking an important milestone. This is the first neurostimulation therapy for obstructive sleep apnea (OSA) to be offered in the area. It gives patients who have trouble with continuous positive airway pressure (CPAP) devices more treatment choices.

The Genio therapy is meant to make it easier for people around the world to get effective treatments for OSA, which will put Nyxoah in a competitive place in the market. Through more widespread access of its cutting-edge treatments, the company hopes to give people with OSA hope.

Nyxoah is a medical technology business that uses neuromodulation to find new ways to treat OSA. Its most popular product, Genio, is a hypoglossal neuromodulation gadget that works on OSA and does not need batteries. It is becoming more popular all over the world. In Europe, the company has been given the CE mark, and in the US, they are in the process of getting FDA clearance.